Twinstrand Biosciences
Seattle, US · Delaware corporation · 2 known investors
TwinStrand develops Duplex Sequencing technology, a genomic platform for improving accuracy in clinical medicine and life sciences research applications. The company works with partners to translate genomic research into products for human health and scientific discovery.
BiotechData & InfrastructureDeep TechMedical Devices
Founders & leadership
JS
Jesse SalkFounder
KB
Kellie BickelExecutive
EC
Elena CantExecutive
KD
Karen DabbsExecutive
Board
CW
Chad WaiteBoard director
MP
SD
Steve DowBoard director
SS
Soma SomasegarBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$85M disclosed across 6 rounds · 2016–2023
▶$10.3MraisedJun 2023 · 9 investors · Other TechnologyRule 506(b)
▶$10.3MraisedJun 2023 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MIKE PELLINIDirector
- JASON MYERSDirector
- KAREN DABBSExecutive Officer
- SOMA SOMASEGARDirector
- DAVID CANNERDirector
- RONNIE ANDREWSExecutive Officer
- CHAD WAITEDirector
- Offering amount
- $25.7M
- Amount sold
- $10.3M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedMay 2021 · 21 investors · Other TechnologyRule 506(b)
▶$50MraisedMay 2021 · 21 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Chad WaiteDirector
- Jesse SalkExecutive Officer, Director, Promoter
- Kellie BickelExecutive Officer
- Michael PelliniDirector
- Steve DowDirector
- Soma SomasegarDirector
- Elena CantExecutive Officer
- Karen DabbsExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.3MraisedDec 2019 · 45 investors · Other TechnologyRule 506(b)
▶$16.3MraisedDec 2019 · 45 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Jesse SalkExecutive Officer, Director, Promoter
- Chad WaiteExecutive Officer, Director
- Michele FernandesExecutive Officer
- Terry MyersonDirector
- Steve DowDirector
- Offering amount
- $16.3M
- Amount sold
- $16.3M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.2MraisedAug 2018 · 23 investors · BiotechnologyRule 506(b)
▶$1.2MraisedAug 2018 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve DowDirector
- Christopher BenoitExecutive Officer, Director
- Jesse SalkExecutive Officer, Director, Promoter
- Lawrence LoebDirector, Promoter
- Offering amount
- $4M
- Amount sold
- $1.2M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5.3MraisedSep 2017 · 39 investors · BiotechnologyRule 506(b)
▶$5.3MraisedSep 2017 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve DowDirector
- Chad Waite, Jr.Executive Officer, Director
- Linden RhoadsDirector
- Chris IgielskiExecutive Officer, Director
- Lawrence LoebDirector, Promoter
- Jesse SalkExecutive Officer, Director, Promoter
- Offering amount
- $5.5M
- Amount sold
- $5.3M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.9MraisedJun 2016 · 18 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KrandaExecutive Officer, Director, Promoter
- Jesse SalkDirector, Promoter
- Michael SchmittDirector, Promoter
- Chad Waite, Jr.Director
- Linden RhoadsDirector
- Lawrence LoebDirector, Promoter
- Offering amount
- $2.3M
- Amount sold
- $1.9M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapGenomeweb14 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.
Strandtx11 shared keywordsStrand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases. The company has created an mRNA platform with cell-selective targeting capabilities to deliver therapeutic payloads within the body.
Twist Bioscience9 shared keywordsTwist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.
IDbyDNA7 shared keywordsScalable, high throughput DNA sequencing platforms.
Companies competing with Twinstrand Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Twinstrand Biosciences do?
- TwinStrand develops Duplex Sequencing technology, a genomic platform for improving accuracy in clinical medicine and life sciences research applications. The company works with partners to translate genomic research into products for human health and scientific discovery.
- Who founded Twinstrand Biosciences?
- Twinstrand Biosciences was founded by Jesse Salk.
- Who are Twinstrand Biosciences's investors?
- Twinstrand Biosciences's investors include Madrona Venture Group, S32.
- How much funding has Twinstrand Biosciences raised?
- Twinstrand Biosciences has disclosed $85M raised across 6 rounds.
- Where is Twinstrand Biosciences headquartered?
- Twinstrand Biosciences is headquartered in Seattle, US.